Enovix Shareholder Reminder: Early Warrant Expiration Price Condition
Rhea-AI Summary
Enovix (Nasdaq: ENVX) announced that its common stock has traded above $10.50 for nine consecutive trading days since the distribution of warrants. The company's stock closed at $10.71 per share, with warrants trading at $1.96 in-the-money based on their $8.75 exercise price.
The warrants' earliest expiration date is set for August 19, 2025, contingent on the stock maintaining above $10.50 for 20 out of 30 trading days. CFO Ryan Benton noted that eleven trading days remain before potential warrant expiration, after which warrants will become non-tradable and non-exercisable.
Positive
- Warrants are currently $1.96 in-the-money, providing value for warrant holders
- Stock price maintaining strong performance above $10.50 threshold
Negative
- Potential dilution if warrants are exercised
- Limited time remaining for warrant holders to make decisions
Insights
Enovix warrant holders face potential early expiration as stock price meets 9 of 20 required days above $10.50 threshold.
Enovix Corporation has announced that its common stock has traded above
This development is significant for warrant holders who now face a potential accelerated timeline. If Enovix stock continues trading above the
The situation creates a strategic decision point for warrant holders who must now consider whether to:
- Exercise their warrants immediately to lock in the current
22.4% discount to market price - Sell their warrants on the open market to capture remaining time value
- Wait to see if the early expiration condition is met, recognizing the risk of potential value loss
For Enovix, if all warrants are exercised, this would represent an immediate capital infusion at the
Enovix Warrants: 9 of 9 Trading Days Above
FREMONT, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Enovix Corporation (Nasdaq: ENVX, ENVXW) (“Company” or “Enovix”), a leader in advanced silicon battery technology, today announced that the price of its common stock has exceeded
The earliest expiration date for the Warrants remains August 19, 2025, subject to Enovix common stock continuing to trade above
Ryan Benton, Chief Financial Officer, stated, “We’ve now completed nine consecutive trading days out of the twenty days required to trigger early expiration. There may be as few as eleven trading days left prior to expiration of the Warrants, after which the Warrants will no longer be tradable or exercisable. In the meantime, we encourage shareholders to act according to the timeline that best fits their individual circumstances.”
Enovix expects to provide further periodic updates, including if and when the Early Expiration Price Condition is met.
Further Information Relating to the Warrants
For more information relating to the exercise mechanics and other terms of the Warrants, please refer to the materials filed by the Company with the Securities and Exchange Commission (the “SEC”) available at https://www.sec.gov and the information posted on the Company’s website at https://www.enovix.com/enovix-warrant-dividend.
About Enovix Corporation
Enovix is a leader in advancing lithium-ion battery technology with its proprietary cell architecture designed to deliver higher energy density and improved safety. The Company’s breakthrough silicon-anode batteries are engineered to power a wide range of devices from wearable electronics and mobile communications to industrial and electric vehicle applications. Enovix’s technology enables longer battery life and faster charging, supporting the growing global demand for high-performance energy storage. Enovix holds a robust portfolio of issued and pending patents covering its core battery design and manufacturing process.
Enovix is headquartered in Silicon Valley with facilities in India, South Korea and Malaysia. For more information visit https://enovix.com and follow us on LinkedIn.
No Offer or Solicitation
This press release is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The issuance of the Warrants has not been registered under the Securities Act of 1933, as amended (the “Securities Act”), as the distribution of a Warrant for no consideration does not constitute a sale of a security under Section 2(a)(3) of the Securities Act. A Form 8-A registration statement and prospectus supplement describing the terms of the Warrants were filed with the SEC and are available on the SEC’s website located at https://www.sec.gov. Holders of Warrants should read the prospectus supplement carefully, including the Risk Factors section included and incorporated by reference therein. This press release contains a general summary of the Warrants. Please read the Warrant Agreement filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on July 21, 2025 as it contains important information about the terms of the Warrants.
Forward‐Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, about us, the Warrants and our business that involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or our future financial or operating performance and can be identified by words such as anticipate, believe, continue, could, estimate, expect, intend, may, might, plan, possible, potential, predict, should, would and similar expressions that convey uncertainty about future events or outcomes. Forward-looking statements in this press release include, without limitation, our expectations regarding the Early Expiration Price Condition and the anticipated trading prices of our common stock. Actual results and outcomes could differ materially from these forward-looking statements as a result of certain risks and uncertainties, including, without limitation, those risks and uncertainties and other potential factors set forth in our filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of our most recently filed annual report on Form 10-K and quarterly reports on Form 10-Q and other documents that we have filed, or that we will file, with the SEC. For a full discussion of these risks, please refer to Enovix’s filings with the SEC, including its most recent Form 10-K and Form 10-Q, available at https://ir.enovix.com and www.sec.gov. Any forward-looking statements made by us in this press release speak only as of the date on which they are made and subsequent events may cause these expectations to change. We disclaim any obligations to update or alter these forward-looking statements in the future, whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact:
Robert Lahey
ir@enovix.com
Chief Financial Officer:
Ryan Benton
ryan.benton@enovix.com
FAQ
When do Enovix (ENVX) warrants expire?
What is the current exercise price for Enovix (ENVX) warrants?
How many trading days has Enovix (ENVX) stock traded above $10.50?
What happens to Enovix (ENVX) warrants after expiration?
What is the current trading price of Enovix (ENVX) stock?
